inVentiv adds partners to extend global reach
Addition of partners based in Asia, Europe and Africa marks a significant expansion to the network inVentiv set up last year. Originally Argentina-based ActivaCRO was the sole member of the alliance but three more companies have now been added.
This allows inVentiv to offer services “on a global scale where it is needed today”, commented Michael Hlinak, president and CEO of inVentiv Clinical. Hlinak added that the alliance “represents significant operational integration and access to rapidly developing clinical research markets”.
PPC has joined the alliance, boosting inVentiv’s capabilities in Asia Pacific. The Taiwan-based contract research organisation (CRO) operates in Japan, China, Korea, Hong Kong, Singapore, Malaysia and Australia, providing a range of services spanning Phase I to IV clinical trials.
inVentiv has also partnered with Frankfurt, Germany-based Ecron Acunova. This extends inVentiv’s reach in Europe, allowing it to offer clients Phase I to IV research, clinical data management and pharmacokinetic (PK) / pharmacodynamic (PD) services in the region.
Ecron Acunova has prior links to the alliance through an ongoing relationship with Essential CRO, acquired by inVentiv this year, and an earlier partnership with PPC in Taiwan.
The final addition to the alliance is Pretoria, South Africa-based RDDA. Joining with RDDA allows inVentiv to offer regulatory, project management and monitoring support in countries including South Africa, Botswana, Zambia, Kenya, Mozambique and Zimbabwe.
Joining with these companies expands inVentiv’s in-house network. inVentiv operates wholly-owned units in India, Brazil, Spain, Taiwan and the US.
Earlier this month THL said it had entered into a definitive agreement to acquire inVentiv Health, the group which includes inVentiv Clinical, for $1.1bn (€900m).
